DE69320096T2 - Verabreichungssystem für Östradiol - Google Patents

Verabreichungssystem für Östradiol

Info

Publication number: DE69320096T2
Authority: DE; Germany
Prior art keywords: estradiol; adhesive; progestin; solvent; mixture
Prior art date: 1992-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69320096T

Other languages

English (en)

Other versions

DE69320096D1 (de

Inventor

Jacques Dr Gonella

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Antares Pharma IPL AG

Original Assignee

Permatec Technologie AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-08

Filing date

1993-05-07

Publication date

1998-12-10

1993-05-07 Application filed by Permatec Technologie AG filed Critical Permatec Technologie AG

1998-09-10 Publication of DE69320096D1 publication Critical patent/DE69320096D1/de

1998-12-10 Application granted granted Critical

1998-12-10 Publication of DE69320096T2 publication Critical patent/DE69320096T2/de

2013-05-08 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title abstract 5
229960005309 estradiol Drugs 0.000 title abstract 5
229930182833 estradiol Natural products 0.000 title abstract 5
239000000853 adhesive Substances 0.000 abstract 4
230000001070 adhesive effect Effects 0.000 abstract 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
239000011505 plaster Substances 0.000 abstract 2
239000000583 progesterone congener Substances 0.000 abstract 2
239000002904 solvent Substances 0.000 abstract 2
229920002367 Polyisobutene Polymers 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
238000002657 hormone replacement therapy Methods 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
230000035699 permeability Effects 0.000 abstract 1
229920000058 polyacrylate Polymers 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
150000004671 saturated fatty acids Chemical class 0.000 abstract 1
238000007910 systemic administration Methods 0.000 abstract 1
235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

DE69320096T 1992-05-08 1993-05-07 Verabreichungssystem für Östradiol Expired - Fee Related DE69320096T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH148792		1992-05-08
US08/358,897 US5665377A (en)	1992-05-08	1994-12-19	Administration system for estradiol

Publications (2)

Publication Number	Publication Date
DE69320096D1 DE69320096D1 (de)	1998-09-10
DE69320096T2 true DE69320096T2 (de)	1998-12-10

Family

ID=25687798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69320096T Expired - Fee Related DE69320096T2 (de)	1992-05-08	1993-05-07	Verabreichungssystem für Östradiol

Country Status (11)

Country	Link
US (1)	US5665377A (de)
EP (1)	EP0569338B1 (de)
JP (1)	JP2960832B2 (de)
AT (1)	ATE169213T1 (de)
AU (1)	AU670273B2 (de)
CA (1)	CA2095789C (de)
DE (1)	DE69320096T2 (de)
DK (1)	DK0569338T3 (de)
ES (1)	ES2121975T3 (de)
NZ (1)	NZ247549A (de)
ZA (1)	ZA933180B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5474783A (en) *	1988-03-04	1995-12-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4400770C1 (de) *	1994-01-13	1995-02-02	Lohmann Therapie Syst Lts	Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
JP3534775B2 (ja) *	1995-06-07	2004-06-07	オーソ―マクニールファーマシューティカル，インコーポレイテッド	１７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US5910403A (en) *	1997-05-15	1999-06-08	The Regents Of University Of California	Methods for measuring cellular proliferation and destruction rates in vitro and in vivo
US6692763B1 (en)	1998-11-19	2004-02-17	The Regents Of The University Of California	Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) *	1997-11-21	1999-04-06	Kaiser Foundation Health Plan, Inc.	Methods for treating postmenopausal women using ultra-low doses of estrogen
FR2776191B1 (fr) *	1998-03-23	2002-05-31	Theramex	Composition hormonale topique a effet systemique
GB9828480D0 (en) *	1998-12-24	1999-02-17	Dermatech Limited	Transdermal drug delivery system
WO2000053226A1 (fr) *	1999-03-11	2000-09-14	Saitama Daiichi Pharmaceutical Co., Ltd.	Compositions facilitant l'absorption cutanee
DE10019171A1 (de) *	2000-04-07	2001-10-18	Schering Ag	Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US7001587B2 (en) *	2001-10-24	2006-02-21	The Regents Of The University Of California	Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water
DE10159120B4 (de) *	2001-12-01	2006-08-17	Lts Lohmann Therapie-Systeme Ag	Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
CA2475924C (en) *	2002-02-12	2016-03-29	The Regents Of The University Of California	Non-invasive method for measuring rates of biosynthesis of biological molecules by label incorporation
WO2004011426A2 (en) *	2002-07-30	2004-02-05	The Regents Of The University Of California	Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
WO2004021863A2 (en) *	2002-09-04	2004-03-18	The Regents Of The University Of California	Methods for measuring rates of replication and death of nfectious microbial agents in an infected host organism
DK1546373T3 (da)	2002-09-13	2009-03-30	Univ California	Fremgangsmåder til måling af hastigheder af revers cholesteroltransport in vivo som et indeks for antiatherogenese
US20070248540A1 (en) *	2002-09-16	2007-10-25	The Regents Of The University Of California	Biochemical methods for measuring metabolic fitness of tissues or whole organisms
SG152922A1 (en) *	2002-11-04	2009-06-29	Univ California	Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
AU2004220541B2 (en)	2003-03-12	2009-03-26	Epitome Pharmaceuticals Limited	Rapidly absorbing lipophilic skin compositions and uses therefor
US7858607B2 (en) *	2003-03-14	2010-12-28	Mamchur Stephen A	System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7262020B2 (en) *	2003-07-03	2007-08-28	The Regents Of The University Of California	Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
EP1682102A2 (de) *	2003-09-10	2006-07-26	Noven Pharmaceuticals, Inc.	Mehrschichtige transdermale arzneimittelabgabevorrichtung
RU2356580C2 (ru) *	2003-10-28	2009-05-27	Новен Фармасьютикалз, Инк	Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств
US20050202406A1 (en)	2003-11-25	2005-09-15	The Regents Of The University Of California	Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
TW200538738A (en)	2004-02-20	2005-12-01	Univ California	Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
AU2005222430A1 (en) *	2004-03-11	2005-09-22	The Regents Of University Of California	Temporal or spatial characterization of biosynthetic events in living organisms by isotopic fingerprinting under conditions of imposed isotopic gradients
US20050238577A1 (en) *	2004-03-29	2005-10-27	The Regents Of The University Of California	Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
WO2006041911A2 (en)	2004-10-08	2006-04-20	Noven Pharmaceuticals, Inc.	Device transdermal administration of drugs including acrylic polymers
WO2006041907A2 (en)	2004-10-08	2006-04-20	Noven Pharmaceuticals, Inc.	Transdermal delivery of estradiol
US20060251576A1 (en) *	2005-05-03	2006-11-09	The Regents Of The University Of California	Methods for measuring cholesterol metabolism and transport
TW200711660A (en)	2005-06-10	2007-04-01	Univ California	Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
AU2006299833B2 (en)	2005-10-12	2012-04-12	Besins Healthcare Luxembourg Sarl	Improved testosterone gel and method of use
US8231906B2 (en)	2008-07-10	2012-07-31	Noven Pharmaceuticals, Inc.	Transdermal estrogen device and delivery
US20130032163A1 (en) *	2011-08-03	2013-02-07	Nail Couture L.A. Llc	System and method for nail foil application
WO2013036885A1 (en)	2011-09-08	2013-03-14	The Regents Of The University Of California	Metabolic flux measurement, imaging and microscopy
US20140353486A1 (en)	2011-12-07	2014-12-04	Glaxosmithkline Llc	Methods for determining total body skeletal muscle mass
US9134319B2 (en)	2013-03-15	2015-09-15	The Regents Of The University Of California	Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5843368B2 (ja) *	1980-10-30	1983-09-27	日東電工株式会社	消炎鎮痛貼付剤
US4626539A (en) *	1984-08-10	1986-12-02	E. I. Dupont De Nemours And Company	Trandermal delivery of opioids
US4818540A (en) *	1985-02-25	1989-04-04	Rutgers, The State University Of New Jersey	Transdermal fertility control system and process
US4764381A (en) *	1985-12-06	1988-08-16	Key Pharmaceuticals, Inc.	Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US5145682A (en) *	1986-05-30	1992-09-08	Rutgers, The State University Of New Jersey	Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5023084A (en) *	1986-12-29	1991-06-11	Rutgers, The State University Of New Jersey	Transdermal estrogen/progestin dosage unit, system and process
US4816258A (en) *	1987-02-26	1989-03-28	Alza Corporation	Transdermal contraceptive formulations
US4994267A (en) *	1988-03-04	1991-02-19	Noven Pharmaceuticals, Inc.	Transdermal acrylic multipolymer drug delivery system
DE58909570D1 (de) *	1988-10-27	1996-02-22	Schering Ag	Mittel zur transdermalen applikation enthaltend gestoden
CA2004203A1 (en) *	1988-12-01	1990-06-01	Sharad K. Govil	Compositions for transdermal delivery of estradiol
DE3933460A1 (de) *	1989-10-06	1991-04-18	Lohmann Therapie Syst Lts	Oestrogenhaltiges wirkstoffpflaster
AR246186A1 (es) *	1989-11-17	1994-07-29	Beta Pharm Co	Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
US5122382A (en) *	1990-10-29	1992-06-16	Alza Corporation	Transdermal contraceptive formulations, methods and devices

1993
- 1993-04-28 JP JP5102325A patent/JP2960832B2/ja not_active Expired - Fee Related
- 1993-05-05 NZ NZ247549A patent/NZ247549A/en unknown
- 1993-05-06 ZA ZA933180A patent/ZA933180B/xx unknown
- 1993-05-07 DK DK93810336T patent/DK0569338T3/da not_active Application Discontinuation
- 1993-05-07 AU AU38459/93A patent/AU670273B2/en not_active Ceased
- 1993-05-07 EP EP93810336A patent/EP0569338B1/de not_active Expired - Lifetime
- 1993-05-07 AT AT93810336T patent/ATE169213T1/de not_active IP Right Cessation
- 1993-05-07 ES ES93810336T patent/ES2121975T3/es not_active Expired - Lifetime
- 1993-05-07 DE DE69320096T patent/DE69320096T2/de not_active Expired - Fee Related
- 1993-05-07 CA CA002095789A patent/CA2095789C/en not_active Expired - Fee Related
1994
- 1994-12-19 US US08/358,897 patent/US5665377A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2095789A1 (en)	1993-11-09
JPH0614986A (ja)	1994-01-25
DE69320096D1 (de)	1998-09-10
JP2960832B2 (ja)	1999-10-12
AU670273B2 (en)	1996-07-11
EP0569338B1 (de)	1998-08-05
ATE169213T1 (de)	1998-08-15
EP0569338A1 (de)	1993-11-10
CA2095789C (en)	2002-12-03
ES2121975T3 (es)	1998-12-16
AU3845993A (en)	1993-11-11
US5665377A (en)	1997-09-09
NZ247549A (en)	1995-12-21
DK0569338T3 (da)	1999-05-03
ZA933180B (en)	1994-06-14

Legal Events

Date	Code	Title	Description
1999-09-02	8364	No opposition during term of opposition
2004-03-18	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
ATE169213T1 (de)	1998-08-15	Verabreichungssystem für östradiol
US4863738A (en)	1989-09-05	Skin permeation enhancer compositions using glycerol monooleate
DE3870504D1 (de)	1992-06-04	Transdermale therapeutische systeme fuer wirkstoffkombinationen.
KR940013496A (ko)	1994-07-15	경피투여시스템
PT96028A (pt)	1991-09-13	Processo para a preparacao de um sistema terapeutico transdermico contendo 17-(ciclopropil-metil)-alfa-(1,1-dimetil-etil)-4,5-epoxi-18,19-di-hidro-3-hidroxi-6-metoxi-alfa-metil-6,14-etenomorfinano-7-metanol(buprenorfinal) como ingrediente activo
CA2227538A1 (en)	1997-02-06	Hormone patch
GB2156215B (en)	1988-03-02	Percutaneous absorption type adhesive pharmaceutical preparation
KR900005969A (ko)	1990-05-07	게스토덴을 함유하는 경피 투여용 제제
ATE164769T1 (de)	1998-04-15	Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
KR20000070178A (ko)	2000-11-25	호르몬 방출용 트랜스더멀 치료 시스템
IL106512A (en)	1997-07-13	Plaster for the transdermal application of steroid hormones and process for the preparation thereof
GB1216908A (en)	1970-12-23	Medicated adhesive tape
ES2198584T3 (es)	2004-02-01	Parche para aplicacion transdermica de pergolid.
CA2183544A1 (en)	1995-08-24	Desogestrel-containing transdermal application agent
ATE240722T1 (de)	2003-06-15	Transdermales abgabesystem, das ein östrogen enthält
JPS56140927A (en)	1981-11-04	Medical member
KR920700704A (ko)	1992-08-10	pH-조절된 조건하 약리학적 화합물 투여용 개선된 경피체계
KR930023040A (ko)	1993-12-18	에스트라디올의 경피 투여용 접착 플라스터 및 그 제조 방법
IL81540A0 (en)	1987-09-16	Dermal and transdermal patches having a discontinuous pattern adhesive layer
JP3002491B2 (ja)	2000-01-24	経皮吸収製剤
CA2144441A1 (en)	1994-03-31	Dexpanthenol-containing plaster for the transdermal application of steroid hormones